CHINOOK THERAPEUTICS INC (KDNY) Stock Price, Forecast & Analysis
USA - NASDAQ:KDNY - US16961L1061 - Common Stock
KDNY Key Statistics, Chart & Performance
The current stock price of KDNY is 40.39 USD. In the past month the price increased by 2.98%. In the past year, price increased by 95.69%.
KDNY Latest News, Press Relases and Analysis
KDNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.15 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About KDNY
Company Profile
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 214 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
Company Info
CHINOOK THERAPEUTICS INC
400 Fairview Avenue North, Suite 900
Seattle WASHINGTON 98102 US
CEO: Eric L. Dobmeier
Employees: 214
Phone: 12064857051.0
CHINOOK THERAPEUTICS INC / KDNY FAQ
Can you describe the business of CHINOOK THERAPEUTICS INC?
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 214 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
Can you provide the latest stock price for CHINOOK THERAPEUTICS INC?
The current stock price of KDNY is 40.39 USD. The price increased by 0.22% in the last trading session.
Does KDNY stock pay dividends?
KDNY does not pay a dividend.
What is the ChartMill technical and fundamental rating of KDNY stock?
KDNY has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is KDNY stock listed?
KDNY stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for CHINOOK THERAPEUTICS INC?
The Revenue of CHINOOK THERAPEUTICS INC (KDNY) is expected to decline by -50.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does CHINOOK THERAPEUTICS INC (KDNY) report earnings?
CHINOOK THERAPEUTICS INC (KDNY) will report earnings on 2023-11-08, after the market close.
KDNY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KDNY. When comparing the yearly performance of all stocks, KDNY is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
KDNY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KDNY. No worries on liquidiy or solvency for KDNY as it has an excellent financial health rating, but there are worries on the profitability.
KDNY Financial Highlights
Over the last trailing twelve months KDNY reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -107.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
KDNY Forecast & Estimates
17 analysts have analysed KDNY and the average price target is 41.11 USD. This implies a price increase of 1.77% is expected in the next year compared to the current price of 40.39.
For the next year, analysts expect an EPS growth of -13.68% and a revenue growth -50.48% for KDNY